Q-omics provides the consensus-scored MIR106B profile across patient tissues and cancer cell-line models. MIR106B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MIR106B is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, MIR106B RNA expression shows 12,057 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, BRCA, and UVM as cancer lineages where MIR106B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR106B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR106B survival associations across molecular data types. MIR106B RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR106B RNA expression–survival associations across cancer types. High MIR106B expression shows unfavorable associations in LGG, HNSC, CESC and COAD, but favorable associations in PAAD and SARC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for MIR106B RNA expression.
This table summarizes MIR106B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR106B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR106B shows lower tumor expression in BRCA, KIRC, LUAD and UCEC and higher tumor expression in CHOL and STAD. The BRCA box plot shows higher MIR106B RNA expression in normal versus tumor tissue (log2 FC = −0.439, t-test p < 0.001).
This table shows molecular features associated with MIR106B in patient tissues and cancer cell lines. In patient samples, MIR106B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
